EN CN

NEWS RELEASES

YEAR

ALL

2019

2018

2017

2016

2015

2014

CANBRIDGE PHARMACEUTICALS’ HUNTERASE® GRANTED PRIORITY REVIEW BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION SEP 09, 2019
CANBRIDGE PHARMACEUTICALS APPOINTS SENIOR VICE PRESIDENT, RARE DISEASE COMMERCIAL OPERATIONS JUL 30, 2019
CANBRIDGE PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR HUNTERASE® FOR THE TREATMENT OF HUNTER SYNDROME IN CHINA JUL 29, 2019
CANBRIDGE PHARMACEUTICALS APPOINTS CHIEF FINANCIAL OFFICER AND INTERIM CHIEF MEDICAL OFFICER APR 25, 2019
CANBRIDGE PHARMACEUTICALS AND WUXI BIOLOGICS EXPAND RARE DISEASE THERAPEUTICS PARTNERSHIP JAN 08, 2019
CANBRIDGE PHARMACEUTICALS AND GC PHARMA ANNOUNCE GREATER CHINA LICENSING AGREEMENT FOR HUNTERASE™ FOR HUNTER SYNDROME JAN 07, 2019

«
1
2
3
4
5
6
7
8
9
»

PARTNERSHIP &
RECOGNITION

WORKING AT CANBRIDGE

EMPLOYEES’ WORD

OPENING POSITIONS

TEL: 86-10-84148018

FAX: 86-10-84148017

Product Hotline: 86-400-821-5085

ADD: Suite 301，3F，Timeloit，No.17 RongChuang Road，Chaoyang District， Beijing，China

EMAIL: info@canbridgepharma.com

Adverse Events Reporting: PV@canbridgepharma.com

Copyright ©:CANbridge Life Sciences Ltd. ICP:12036158-1 Powered By Clouddream